問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 1,704

    Total Beds

  • 806

    Total Doctors

  • ctc@ms.kmuh.org.tw
  • Yu-Sam Lin
  • 886-7-3121101#6643
  • 807Kaohsiung CityKaohsiung SanminNo.100, Tzyou 1st Rd., Sanmin Dist.,Sanmin,Kaohsiung City 807

Recruiting Trial

537Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1238Cases

2015-12-01 - 2021-12-31

Phase III

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer′s Disease

  • Condition/Disease

    Alzheimer′s disease

  • Test Drug

    Aducanumab

Participate Sites
8Sites

Terminated7Sites

劉景寬
Kaohsiung Municipal Gangshan Hospital

未分科

劉景寬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2009-09-01 - 2013-09-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-03-31 - 2019-04-30

Phase III

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Unresectable Hepatocellular Carcinoma

  • Test Drug

    Lenvatinib

Participate Sites
12Sites

Not yet recruiting12Sites

2012-07-10 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2012-12-03 - 2018-09-05

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2009-10-31 - 2013-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2012-01-01 - 2013-05-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2012-01-01 - 2018-12-31

Phase II

(OSKIRA-Asia-1X): A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Fostamatinib

Participate Sites
8Sites

Terminated8Sites

2007-03-01 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-08-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 100 101 102 103 104 124
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB